ClinicalTrials.gov record NCT07805967

Multi-Center Study of Natural History in Atypical Parkinsonian Syndromes (MAPS-NH)

Record copied from ClinicalTrials.gov: Oct 10, 2026AI summaries generated: Sep 16, 2026

Multi-Center Study of Natural History in Atypical Parkinsonian Syndromes (MAPS-NH)

StatusRecruitingThe study is currently enrolling participants. Only the study team can say whether a particular person can join.
Study typeObservationalA study in which researchers do not assign participants to a treatment or other intervention. They observe or measure what happens, which may include study visits, tests, questionnaires or a review of medical records.
Age18 years old and older
SexAll
LocationChina
AI summaryWhat this study is about, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

This is a prospective observational study following people diagnosed with MSA, DLB, PSP, or CBD. Participants are assessed every 6 months for up to 3 years to record clinical changes, biomarkers, and imaging patterns. No treatments are assigned—the study collects data to build clinical and biological databases.

What it is studying. The study aims to describe how different atypical parkinsonian syndromes change over time, including rates of motor and non-motor symptom progression and characteristic imaging evolution, and to find biomarkers with early predictive value.

What the researchers hope to learn. To clarify variations in the natural course of atypical parkinsonian syndromes, establish a comprehensive assessment framework for these conditions, build clinical and biological databases, and identify biomarkers that may predict disease course early.

What this study is about

The study's own summary, as published on ClinicalTrials.gov. Underlined terms have a short explanation.

This goal of this observational study is to clarify the variations in the natural course of atypical parkinsonian syndromes (APS, including MSA, DLB, PSP, and CBD), such as the progression rate of motor and non-motor symptoms and characteristic imaging evolution patterns. Establish a comprehensive assessment framework for APS, and develop clinical and biological databases to identify biomarkers with early predictive value.

Interventions being studied

Being studied in this trial does not mean the treatment or procedure is approved or available for this condition.

Other
  • We did not apply any interventions; only observational research was conducted.

Eligibility

The criteria exactly as listed on ClinicalTrials.gov. Only the study team can say whether they apply to you.

Inclusion criteria

  • MSA : Meets the "probable MSA" criteria in the 2022 Chinese expert consensus on MSA diagnosis (MSA-P or MSA-C subtype); disease duration ≤3 years (from onset of first motor symptoms) .
  • DLB : Meets "probable DLB" criteria per the 2017 McKeith diagnostic criteria; MMSE ≥18 (to exclude severe dementia confounding assessment) .
  • PSP : Meets "probable PSP-Richardson syndrome" criteria per the 2017 PSP diagnostic standards; vertical gaze palsy or postural instability with duration ≤2 years .
  • CBD : Meets "probable CBD" criteria per the 2019 Chinese expert consensus on corticobasal degeneration diagnosis and treatment; asymmetric cortical symptoms (apraxia/dystonia/alien limb).

Exclusion criteria

  • Parkinson's disease , spinocerebellar ataxia (SCA) and other secondary autonomic failure .
  • Vascular parkinsonism , Parkinsonism caused by stroke , tumor , or immune-mediated encephalitis .

Study description and what participation involves

The registry record has no detailed description beyond the summary above.

AI summaryWhat participation may involve, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

Participants are followed for up to 3 years with study visits every 6 months. At those visits researchers record clinical exams and symptom ratings focused on motor and non‑motor features, and they assess imaging changes and biomarkers over time. The study is strictly observational — no treatments or interventions are given by the study. The registry record does not specify any invasive procedures (for example lumbar puncture or biopsies) or exact sample types; the study team would provide those details if applicable.

How the study is structured. A prospective cohort observational study. Participants receive no experimental treatments; they take part in scheduled assessments every 6 months for up to 36 months. Assessments focus on clinical features, biomarker measurements, and imaging changes as defined by the study protocol.

Questions you could ask

These questions are suggestions for a conversation with the study team or your own clinician, not advice.

  • This is an observational study, so the study itself gives no treatment. What would taking part involve for me, and would it change my usual care?
  • The listed sites are in China. Is any of them reachable for me, and does the study help with travel?
  • Which of the eligibility criteria would need to be checked with tests before I could join?

More on multiple system atrophy

This trial is also listed on this site under progressive supranuclear palsy.

Clinical trials76 trials listed for multiple system atrophyEvery trial the registry lists for multiple system atrophy, with recruitment status, phase and sites, updated from ClinicalTrials.gov.See all trials →Research updatesWhat changed in multiple system atrophy researchLatest monthly update: September 2026. Includes: Tube feeding. New research summarized each month in plain language, with links to every source paper.Read the latest update →

Important dates

Study start
Nov 12, 2025
Primary completion
Aug 31, 2030 (estimated)
Study completion
Aug 31, 2030 (estimated)
Target enrollment
500 participants (estimated)
Last updated on registry
Sep 8, 2026
Data verified
Oct 10, 2026

Sponsor and research team

The lead sponsor funds and oversees the trial. A pharmaceutical or biotech company sponsor typically means the study is testing that company's drug or device; a hospital, university, or government agency usually indicates investigator-initiated or publicly funded research.

Lead sponsor
Second Affiliated Hospital of Soochow University

Central study contact

If you're interested in participating, the central contact can answer general questions about the study — including eligibility requirements and how to find a recruiting site near you. Actual eligibility is determined by the site's medical team.

Participating sites (20)

  • Changshu Hospital Affiliated to Nanjing University of Chinese MedicineRecruiting

    Changshu, Jiangsu, 215500 · China

  • The second People's Hospital of Huai'anNot Yet Recruiting

    Huai'an, Jiangsu, 223001 · China

  • The First People's Hospial of KunshanNot Yet Recruiting

    Kunshan, Jiangsu, 215300 · China

  • Jiangsu Province Official HospitalNot Yet Recruiting

    Nanjing, Jiangsu, 210000 · China

  • The Second Affiliated Hospital of Nantong UniversityNot Yet Recruiting

    Nantong, Jiangsu, 226000 · China

  • Jiangsu Province (Suqian) HospitalRecruiting

    Suqian, Jiangsu, 223800 · China

  • The Forth Affiliated Hospital of Soochow UniversityRecruiting

    Suzhou, Jiangsu, 215000 · China

  • The Second Affiliated Hospital of Soochow UniversityRecruiting

    Suzhou, Jiangsu, 215000 · China

  • The Second Affiliated Hospital of Xuzhou Medical UniversityNot Yet Recruiting

    Xuzhou, Jiangsu, 221000 · China

  • Yancheng Third People's HospitalRecruiting

    Yancheng, Jiangsu, 224000 · China

Terms used on this page · explanations by MedicalUpdates.ai

biomarkers
Something measurable in the body, such as a blood test result or an imaging finding, that indicates how a condition or treatment is behaving.
Inclusion Criteria
The conditions a person must meet to be considered for the study, for example a confirmed diagnosis, an age range or a test result.
Exclusion Criteria
The conditions that rule a person out even if they meet the inclusion criteria, for example other illnesses, certain medicines or pregnancy.

The study record on this page is reproduced from ClinicalTrials.gov, a database of the U.S. National Library of Medicine, where it was submitted by the study sponsor. MedicalUpdates.ai does not own this content, is not affiliated with or endorsed by ClinicalTrials.gov, NIH, or the U.S. Government, and does not verify the record. Plain-language notes, the glossary and the questions above are added by this site; text in the boxes marked "AI summary" was written by an AI model and may contain errors. Registry records change over time. Check the original record for the current version and discuss eligibility or participation with a qualified healthcare professional.

← Back to clinical trials